中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
7期
27-28,29
,共3页
马来酸曲美布汀%依帕司他%糖尿病%胃轻瘫%疗效%胃动素
馬來痠麯美佈汀%依帕司他%糖尿病%胃輕癱%療效%胃動素
마래산곡미포정%의파사타%당뇨병%위경탄%료효%위동소
trimebutine maleate%epalrestat%diabetes%gastroparesis%curative effect%motilin
目的：观察马来酸曲美布汀联合依帕司他治疗糖尿病胃轻瘫（DGP）的疗效。方法以2012年1月至2014年10月收治的 DGP 患者200例，随机分为两组，各100例，分别给予马来酸曲美布汀＋依帕司他（治疗组）和单纯马来酸曲美布汀（对照组）治疗。结果治疗组临床总有效率为93.00%，明显高于对照组的74.00%（ P ﹤0.05）。治疗后，治疗组症状评分、神经功能异常率、胃排空率分别为（3.17±2.15）分，（22.46±5.78）%和（72.08±19.41）%，对照组分别为（4.68±2.47）分，（51.67±10.32）%和（55.92±23.09）%，两组比较，差异具有统计学意义（ P ﹤0.05）。治疗后，治疗组胃动素、胃泌素分别为（209.45±62.73）ng / L 和（100.27±28.49）ng / L，明显低于对照组的（408.14±71.28）ng / L 和（167.43±31.08）ng / L（ P ﹤0.05）。结论马来酸曲美布汀联合依帕司他治疗 DGP 具有明显优势，能有效改善患者消化道临床症状和神经功能，促进胃肠道运动。
目的：觀察馬來痠麯美佈汀聯閤依帕司他治療糖尿病胃輕癱（DGP）的療效。方法以2012年1月至2014年10月收治的 DGP 患者200例，隨機分為兩組，各100例，分彆給予馬來痠麯美佈汀＋依帕司他（治療組）和單純馬來痠麯美佈汀（對照組）治療。結果治療組臨床總有效率為93.00%，明顯高于對照組的74.00%（ P ﹤0.05）。治療後，治療組癥狀評分、神經功能異常率、胃排空率分彆為（3.17±2.15）分，（22.46±5.78）%和（72.08±19.41）%，對照組分彆為（4.68±2.47）分，（51.67±10.32）%和（55.92±23.09）%，兩組比較，差異具有統計學意義（ P ﹤0.05）。治療後，治療組胃動素、胃泌素分彆為（209.45±62.73）ng / L 和（100.27±28.49）ng / L，明顯低于對照組的（408.14±71.28）ng / L 和（167.43±31.08）ng / L（ P ﹤0.05）。結論馬來痠麯美佈汀聯閤依帕司他治療 DGP 具有明顯優勢，能有效改善患者消化道臨床癥狀和神經功能，促進胃腸道運動。
목적：관찰마래산곡미포정연합의파사타치료당뇨병위경탄（DGP）적료효。방법이2012년1월지2014년10월수치적 DGP 환자200례，수궤분위량조，각100례，분별급여마래산곡미포정＋의파사타（치료조）화단순마래산곡미포정（대조조）치료。결과치료조림상총유효솔위93.00%，명현고우대조조적74.00%（ P ﹤0.05）。치료후，치료조증상평분、신경공능이상솔、위배공솔분별위（3.17±2.15）분，（22.46±5.78）%화（72.08±19.41）%，대조조분별위（4.68±2.47）분，（51.67±10.32）%화（55.92±23.09）%，량조비교，차이구유통계학의의（ P ﹤0.05）。치료후，치료조위동소、위비소분별위（209.45±62.73）ng / L 화（100.27±28.49）ng / L，명현저우대조조적（408.14±71.28）ng / L 화（167.43±31.08）ng / L（ P ﹤0.05）。결론마래산곡미포정연합의파사타치료 DGP 구유명현우세，능유효개선환자소화도림상증상화신경공능，촉진위장도운동。
Objective To observe the efficacy of trimebutine maleate combined with epalrestat in treating diabetic gastroparesis (DGP) . Methods 200 cases of DGP from January 2012 to October 2014 were taken as the research subjects and were randomly divided into two groups with 100 cases each, and treated by trimebutine maleate plus epalrestat (treatment group) and simple trimebutine maleate (control group) respectively. Results In the treatment group, the total effective rate was 93. 00% which is significantly higher than 74. 00% in the control group( P ﹤ 0. 05) . The symptom score, neural function abnormal rate and gastric emptying rate before treatment had no statistically significant differences between the two groups( P ﹥ 0. 05) . The symptom score, nerve function abnormal rate and gastric emptying rates after treatment in the treatment group were (3. 17 ± 2. 15) points, (22. 46 ± 5. 78)% and (72. 08 ± 19. 41 )% re-spectively; the data in the control group were (4. 68 ± 2. 47) points, (51. 67 ± 10. 32)% and (55. 92 ± 23. 09)% respectively. The dif-ferences between the two groups had statistically significance ( P ﹤ 0. 05). The motilin and gastrin levels after treatment in the treatment group were (209. 45 ± 62. 73) ng / L and (100. 27 ± 28. 49) ng / L respectively, obviously lower than (408. 14 ± 71. 28) ng / L and (167. 43 ± 31. 08) ng / L respectively in the control group. The differences between the two groups had statistical significance ( P ﹤ 0. 05) . Conclusion Trimebutine maleate combined with epalrestat in treating DGP has obvious advantages. It can effectively improve the clini-cal symptoms of digestive tract and nerve function, promote the gastrointestinal movement, and can be used as the first - line drug for treating DGP.
